Novo Nordisk's CagriSema Data Cuts Both Ways as EMA Backs Lilly's Oral Pill

Novo Nordisk handed investors a fresh set of clinical details on Tuesday, but the same 24-hour stretch delivered a reminder that the competitive and regulatory ground beneath Europe's obesity leader is shifting. A post-hoc look at the company's investigational CagriSema showed women losing an average of 25.0% of body weight after 68 weeks, against 3.0% on placebo, according to figures presented at the Menopause Society's annual meeting in San Diego.

The disclosure deserves careful framing. It is a subgroup analysis drawn from the REDEFINE 1 trial, not a new headline readout for the full study population, and it should not be read as a predictor of any individual patient's outcome. What it does is sharpen the picture of how CagriSema performs in a specific segment of the trial — a detail-level addition rather than a fresh primary endpoint.

A Split Verdict From the Sell Side

Analysts marked the day in divergent fashion. Oddo BHF raised its price target on the Danish drugmaker to 305 DKK from 221 DKK while leaving its rating at "Neutral" — a higher marker that stops well short of a buy call. BMO Capital had moved the other way on October 12, trimming its target to $40 from $47 and keeping a "Market Perform" stance.

The Chicago-based broker pointed to tough year-on-year comparators for Ozempic in the US and a shrinking American market share, flagging risks to third-quarter 2026 revenue. Those two notes sit on different planes: one is a clinical footnote, the other a warning about commercial momentum. Neither the CagriSema subgroup numbers nor Oddo BHF's loftier target resolves the operational questions BMO has raised.

Brussels Opens the Door to Lilly

Regulatory news added another layer. Reuters reported that the European Medicines Agency has recommended approval of Foundayo (Orforglipron), Eli Lilly's oral treatment, for both obesity and type-2 diabetes. The endorsement sets up direct European competition for Novo Nordisk's tablet-form Wegovy in the same therapeutic territory.

On the home front, the picture was more encouraging. The EMA's Committee for Medicinal Products for Human Use issued a positive opinion on October 15 recommending a label update for Novo Nordisk's Kyinsu, reinforcing the regulatory footing of that portfolio asset in Europe.

Buyback Keeps Rolling

Capital returns proceeded on schedule. Novo Nordisk said Tuesday that it had repurchased 39,074,179 B-shares since the programme began in February through mid-October, for a total consideration of 10,875,024,304 DKK. The framework remains capped at 15 billion DKK, and the company had already reported earlier interim tallies roughly a week before.

Buybacks shrink the share count and underpin the capital structure — a steady counterweight while strategic questions in metabolic therapies dominate the conversation.

The Tape Tells Its Own Story

Sentiment in the market has been muted. Novo Nordisk closed Tuesday at EUR 34.25, down 0.7% on the prior session, and the stock is off 22% since the start of the year as investors weigh its future positioning against mounting competition. The session's 1.6% gain earlier in the day offered little basis for pinning the move on any single catalyst — least of all on the CagriSema subgroup data or the Oddo BHF target change, whose causal link to the price action is unproven.